37413-91-5

基本信息
泼尼松杂质12
醋酸四烯物(3TR)
布地奈德杂质对照品6
16-四烯-3,20-二酮-21-醋酸酯
21-乙酰氧基孕甾-1,4,9(11),16-四烯-3,20-酮
21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯
21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 100G
2-((8S,10S,13S,14S)-10,13-二甲基-3-氧代-6,7,8,10,12,13,14,15-八氢-3H-环戊二烯并[A]菲-17-基)-2-氧代乙基 乙酸酯
16-tetraen-21-yl
Tetraene acetate[3TR]
Prednisone Impurity 12
Acetate tetraene Matter
Tetraen-acetic acid complex
Pregna-1,4,9(11),16-tetraen
21-Hydroxy-1,4,9(11)-tetraene 21-acetate
21-Acetoxypregna-1,4,9(11),16-tetrene-3,20-dione
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione
物理化学性质
制备方法

4380-55-6

37413-91-5
在氮气保护下,将50 g (0.13 mol) 孕-1,4,9(11)-三烯-3,20-二酮-17-羟基-21-乙酸酯与200 mL吡啶加入反应瓶中,冷却至-15℃,搅拌。随后,加入30 g N-氯琥珀酰亚胺(NCS),并在1小时内缓慢通入17.5 g (0.27 mol) SO2气体,控制反应温度不超过-10℃。通气完毕后,继续搅拌半小时。反应完成后,通过TLC监测,确认生成含有δ16甾族化合物(I)的混合溶液。将该混合溶液倒入300 mL浓盐酸中,加入2000 mL冰水,静置2小时以去除水溶性杂质。分离水层后,浓缩有机层至少量液体,过滤得到固体,60℃干燥后获得47 g δ16甾族化合物(I)。通过高效液相色谱(HPLC)测定,该δ16甾族化合物(I)的纯度为99%。
参考文献:
[1] Patent: CN105254697, 2016, A. Location in patent: Paragraph 0077; 0078; 0079; 0080; 0081
常见问题列表
Δ9,11 derivatives are designed and developed to stably incorporate into cell membranes and inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activities, thus avoiding side effects associated with traditional corticosteroids. VBP15 acts as a lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability.
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | HY-136340 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 37413-91-5 | 5 mg | 312元 |
2025/05/22 | HY-136340 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 37413-91-5 | 10mg | 500元 |
2025/05/22 | HY-136340 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 37413-91-5 | 10mM * 1mLin DMSO | 550元 |